Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

The role of adjuvant chemotherapy in stage II colorectal cancer patients.

Lin HH, Chang YY, Lin JK, Jiang JK, Lin CC, Lan YT, Yang SH, Wang HS, Chen WS, Lin TC, Chang SC.

Int J Colorectal Dis. 2014 Oct;29(10):1237-43. doi: 10.1007/s00384-014-1943-6.

PMID:
25024041
2.

Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients.

Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC.

Ann Surg Oncol. 2013 Sep;20(9):2914-20. doi: 10.1245/s10434-013-2919-4.

PMID:
23760586
3.

The Number of Risk Factors Determines the Outcome Of Stage II Colorectal Cancer Patients.

Lin HH, Yang HL, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, Lan YT, Lin TC, Chen WS, Liang WY, Chang SC.

Hepatogastroenterology. 2014 Jun;61(132):1024-7.

PMID:
26158160
4.

Prognostic value of perineural invasion in patients with stage II colorectal cancer.

Huh JW, Kim HR, Kim YJ.

Ann Surg Oncol. 2010 Aug;17(8):2066-72. doi: 10.1245/s10434-010-0982-7.

PMID:
20182809
5.

The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.

Chu-Yuan H, Jing P, Yi-Sheng W, He-Ping P, Hui Y, Chu-Xiong Z, Guo-Jian L, Guo-Qiang W.

BMC Cancer. 2013 Apr 3;13:177. doi: 10.1186/1471-2407-13-177.

6.

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study.

Artac M, Turhal NS, Kocer M, Karabulut B, Bozcuk H, Yalcin S, Karaagac M, Gündüz S, Isik N, Uygun K.

Tumori. 2014 Mar-Apr;100(2):143-8. doi: 10.1700/1491.16397.

7.

Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH.

World J Gastroenterol. 2014 Jan 7;20(1):264-73. doi: 10.3748/wjg.v20.i1.264.

8.

Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.

Gao S, Tibiche C, Zou J, Zaman N, Trifiro M, O'Connor-McCourt M, Wang E.

JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.

PMID:
26502222
9.
10.

Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.

Park HS, Jung M, Shin SJ, Heo SJ, Kim CG, Lee MG, Beom SH, Lee CY, Lee JG, Kim DJ, Ahn JB.

Ann Surg Oncol. 2016 Mar;23(3):928-35. doi: 10.1245/s10434-015-4951-z.

PMID:
26514121
11.

Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.

Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY.

Ann Surg. 2007 Dec;246(6):1040-6.

PMID:
18043108
12.

Is adjuvant chemotherapy beneficial to high risk stage II colon cancer? Analysis in a single institute.

Lin CC, Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC.

Int J Colorectal Dis. 2009 Jun;24(6):665-76. doi: 10.1007/s00384-009-0634-1.

PMID:
19238405
13.

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H.

Gastroenterology. 2000 Oct;119(4):921-8.

PMID:
11040179
14.

Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.

Hwang JE, Hong JY, Kim JE, Shim HJ, Bae WK, Hwang EC, Jeong O, Park YK, Lee KH, Lee JH, Cho SH, Chung IJ.

Jpn J Clin Oncol. 2015 Jun;45(6):541-6. doi: 10.1093/jjco/hyv031.

PMID:
25759484
15.

Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.

Yun HR, Kim HC, Yun SH, Lee WY.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2466-71. doi: 10.5754/hge10260.

PMID:
23169179
16.

Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer.

Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, Cirak Y, Karaca B, Sezgin C, Karabulut B, Uslu R.

J BUON. 2013 Apr-Jun;18(2):372-6.

PMID:
23818348
17.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

18.

Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.

Huh JW, Lee WY, Park YA, Cho YB, Yun SH, Kim HC, Chun HK.

J Cancer Res Clin Oncol. 2014 Mar;140(3):435-41. doi: 10.1007/s00432-013-1580-4.

PMID:
24414039
19.

FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.

Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K, Nagawa H.

Oncology. 2011;80(1-2):84-91. doi: 10.1159/000328761.

PMID:
21677451
20.

Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials.

Cheng SH, Yen KL, Jian JJ, Tsai SY, Chu NM, Leu SY, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT.

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):717-26.

PMID:
11395240
Items per page

Supplemental Content

Support Center